Huang Jiandi, Li Zhiru, He Dongwei, Li Xin, Wang Yaping, Li Qingxia, Wang Dongmiao, Fan Xiaoyan
Graduate School, Hebei North University, Zhangjiakou, Hebei 075132, P.R. China.
Department of Oncology, Hebei General Hospital, Shijiazhuang, Hebei 050051, P.R. China.
Oncol Lett. 2025 Jun 24;30(3):408. doi: 10.3892/ol.2025.15154. eCollection 2025 Sep.
Human epidermal growth factor receptor 2 (HER2) positivity, including gene amplification and mutation, is uncommon in colorectal cancer (CRC), with an incidence of only ~5%. Targeted HER2 therapy has been shown to be feasible in patients with HER2-positive CRC after the failure of standard treatments. However, the importance of anti-HER2 therapy in patients with HER2-positive CRC is not yet fully reflected in clinical guidelines. The present report describes the case of a 60-year-old female patient who presented with abdominal pain and bloody stools and was diagnosed with rectal adenocarcinoma and liver metastasis. The next-generation sequencing of biopsy tissue obtained during colonoscopy suggested HER2 mutation/amplification. After two cycles of chemotherapy, the tumor marker levels of the patient continued to increase, indicating poor treatment efficacy. The patient subsequently received six cycles of chemotherapy combined with anti-HER2 therapy, leading to a reduction in tumor marker levels and gradual shrinkage of the lesions. After this, the colorectal and liver lesions were surgically removed. There is currently no definitive treatment for HER2-positive CRC. However, the present case highlights a favorable response to anti-HER2 therapy in a patient with HER2-positive metastatic CRC, suggesting that this treatment approach may be beneficial for HER2-positive CRC and warrants further investigation.
人表皮生长因子受体2（HER2）阳性，包括基因扩增和突变，在结直肠癌（CRC）中并不常见，发生率仅约为5%。靶向HER2治疗已被证明在标准治疗失败后的HER2阳性CRC患者中是可行的。然而，抗HER2治疗在HER2阳性CRC患者中的重要性尚未在临床指南中得到充分体现。本报告描述了一名60岁女性患者的病例，该患者出现腹痛和便血，被诊断为直肠腺癌并伴有肝转移。结肠镜检查期间获取的活检组织的二代测序提示HER2突变/扩增。经过两个周期的化疗后，患者的肿瘤标志物水平持续升高，表明治疗效果不佳。该患者随后接受了六个周期的化疗联合抗HER2治疗，导致肿瘤标志物水平降低，病变逐渐缩小。此后，结直肠和肝脏病变被手术切除。目前对于HER2阳性CRC尚无明确的治疗方法。然而，本病例突出了一名HER2阳性转移性CRC患者对抗HER2治疗的良好反应，表明这种治疗方法可能对HER2阳性CRC有益，值得进一步研究。
